Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) Stock Competitors & Peer Comparison
See SUPN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SUPN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SUPN | $41.59 | +9.79% | 2.3B | 13.02 | $3.06 | N/A |
| TAK | $20.08 | +2.06% | 62.4B | 14.10 | $1.39 | +3.59% |
| TEVA | $41.15 | -0.84% | 48.1B | 14.09 | $2.93 | N/A |
| HLN | $10.17 | +0.35% | 44.6B | 20.77 | $0.49 | +1.95% |
| ZTS | $80.05 | +0.84% | 32.9B | 12.09 | $6.58 | +2.62% |
| VTRS | $18.45 | -1.13% | 21B | 7.25 | $2.52 | +2.64% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.18 | -1.57% | 11.7B | 22.15 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.31 | +1.80% | 10.9B | 27.85 | $0.47 | +0.64% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
SUPN vs TAK Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TAK has a market cap of 62.4B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TAK trades at $20.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TAK's P/E ratio is 14.10. In terms of profitability, SUPN's ROE is -0.10%, compared to TAK's ROE of +0.02%. Regarding short-term risk, SUPN is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
SUPN vs TEVA Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TEVA has a market cap of 48.1B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TEVA trades at $41.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TEVA's P/E ratio is 14.09. In terms of profitability, SUPN's ROE is -0.10%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, SUPN is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TEVA's competition here
Haleon plc (NYSE: HLN)
SUPN vs HLN Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, HLN has a market cap of 44.6B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while HLN trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas HLN's P/E ratio is 20.77. In terms of profitability, SUPN's ROE is -0.10%, compared to HLN's ROE of +0.10%. Regarding short-term risk, SUPN is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
SUPN vs ZTS Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ZTS has a market cap of 32.9B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ZTS trades at $80.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ZTS's P/E ratio is 12.09. In terms of profitability, SUPN's ROE is -0.10%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, SUPN is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
SUPN vs VTRS Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, VTRS has a market cap of 21B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while VTRS trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas VTRS's P/E ratio is 7.25. In terms of profitability, SUPN's ROE is -0.10%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, SUPN is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
SUPN vs ITCI Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ITCI's P/E ratio is -180.64. In terms of profitability, SUPN's ROE is -0.10%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, SUPN is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
SUPN vs ELAN Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ELAN has a market cap of 11.7B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ELAN trades at $23.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ELAN's P/E ratio is 22.15. In terms of profitability, SUPN's ROE is -0.10%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, SUPN is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
SUPN vs CTLT Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas CTLT's P/E ratio is -27.84. In terms of profitability, SUPN's ROE is -0.10%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, SUPN is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
SUPN vs RDY Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while RDY trades at $13.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas RDY's P/E ratio is 27.85. In terms of profitability, SUPN's ROE is -0.10%, compared to RDY's ROE of +0.09%. Regarding short-term risk, SUPN is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
SUPN vs ALKS Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ALKS has a market cap of 7.2B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ALKS trades at $44.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ALKS's P/E ratio is 45.23. In terms of profitability, SUPN's ROE is -0.10%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, SUPN is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
SUPN vs LNTH Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while LNTH trades at $100.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas LNTH's P/E ratio is 16.79. In terms of profitability, SUPN's ROE is -0.10%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, SUPN is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
SUPN vs AMRX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, AMRX has a market cap of 6.2B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while AMRX trades at $19.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas AMRX's P/E ratio is 21.51. In terms of profitability, SUPN's ROE is -0.10%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, SUPN is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
SUPN vs RGC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, RGC has a market cap of 5B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while RGC trades at $10.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas RGC's P/E ratio is -1005.00. In terms of profitability, SUPN's ROE is -0.10%, compared to RGC's ROE of -1.61%. Regarding short-term risk, SUPN is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
SUPN vs INDV Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, INDV has a market cap of 4.2B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while INDV trades at $35.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas INDV's P/E ratio is 9.28. In terms of profitability, SUPN's ROE is -0.10%, compared to INDV's ROE of -2.16%. Regarding short-term risk, SUPN is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
SUPN vs HCM Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while HCM trades at $14.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas HCM's P/E ratio is 137.14. In terms of profitability, SUPN's ROE is -0.10%, compared to HCM's ROE of +0.01%. Regarding short-term risk, SUPN is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
SUPN vs ALVOW Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, SUPN's ROE is -0.10%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, SUPN is more volatile compared to ALVOW. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
SUPN vs BHC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while BHC trades at $6.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas BHC's P/E ratio is 1.62. In terms of profitability, SUPN's ROE is -0.10%, compared to BHC's ROE of +0.89%. Regarding short-term risk, SUPN is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check BHC's competition here
Perrigo Company plc (NYSE: PRGO)
SUPN vs PRGO Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, PRGO has a market cap of 2.2B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while PRGO trades at $16.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas PRGO's P/E ratio is 6.44. In terms of profitability, SUPN's ROE is -0.10%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, SUPN is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
SUPN vs DCPH Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas DCPH's P/E ratio is -11.58. In terms of profitability, SUPN's ROE is -0.10%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, SUPN is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
SUPN vs AVDL Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, SUPN's ROE is -0.10%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, SUPN is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
SUPN vs EMBCV Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas EMBCV's P/E ratio is N/A. In terms of profitability, SUPN's ROE is -0.10%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, SUPN is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
SUPN vs DVAX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas DVAX's P/E ratio is -41.89. In terms of profitability, SUPN's ROE is -0.10%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, SUPN is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
SUPN vs ALVO Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ALVO trades at $5.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ALVO's P/E ratio is -8.53. In terms of profitability, SUPN's ROE is -0.10%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, SUPN is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
SUPN vs TRLV Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TRLV trades at $10.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TRLV's P/E ratio is -4.18. In terms of profitability, SUPN's ROE is -0.10%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, SUPN is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
SUPN vs ANIP Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ANIP trades at $73.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ANIP's P/E ratio is 8.84. In terms of profitability, SUPN's ROE is -0.10%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, SUPN is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
SUPN vs TARO Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TARO's P/E ratio is 30.05. In terms of profitability, SUPN's ROE is -0.10%, compared to TARO's ROE of +0.03%. Regarding short-term risk, SUPN is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
SUPN vs PAHC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while PAHC trades at $39.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas PAHC's P/E ratio is 13.42. In terms of profitability, SUPN's ROE is -0.10%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, SUPN is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
SUPN vs PCRX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while PCRX trades at $36.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas PCRX's P/E ratio is 13.98. In terms of profitability, SUPN's ROE is -0.10%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, SUPN is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
SUPN vs ETON Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ETON trades at $50.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ETON's P/E ratio is 129.50. In terms of profitability, SUPN's ROE is -0.10%, compared to ETON's ROE of +0.40%. Regarding short-term risk, SUPN is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
SUPN vs CRON Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while CRON trades at $3.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas CRON's P/E ratio is 16.64. In terms of profitability, SUPN's ROE is -0.10%, compared to CRON's ROE of +0.06%. Regarding short-term risk, SUPN is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
SUPN vs AMPH Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while AMPH trades at $26.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas AMPH's P/E ratio is 8.92. In terms of profitability, SUPN's ROE is -0.10%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, SUPN is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
SUPN vs HROW Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, HROW has a market cap of 1B. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while HROW trades at $28.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas HROW's P/E ratio is -27.96. In terms of profitability, SUPN's ROE is -0.10%, compared to HROW's ROE of -1.04%. Regarding short-term risk, SUPN is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
SUPN vs PETQ Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas PETQ's P/E ratio is 83.73. In terms of profitability, SUPN's ROE is -0.10%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, SUPN is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
SUPN vs COLL Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, COLL has a market cap of 749.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while COLL trades at $23.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas COLL's P/E ratio is 2.89. In terms of profitability, SUPN's ROE is -0.10%, compared to COLL's ROE of +0.16%. Regarding short-term risk, SUPN is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
SUPN vs IRWD Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, IRWD has a market cap of 584.9M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while IRWD trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas IRWD's P/E ratio is 4.54. In terms of profitability, SUPN's ROE is -0.10%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, SUPN is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
SUPN vs BDSI Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas BDSI's P/E ratio is 6.82. In terms of profitability, SUPN's ROE is -0.10%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, SUPN is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
SUPN vs EVO Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, EVO has a market cap of 504.4M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while EVO trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas EVO's P/E ratio is -2.01. In terms of profitability, SUPN's ROE is -0.10%, compared to EVO's ROE of -0.27%. Regarding short-term risk, SUPN is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check EVO's competition here
Evolus, Inc. (NASDAQ: EOLS)
SUPN vs EOLS Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, EOLS has a market cap of 486.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while EOLS trades at $7.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas EOLS's P/E ratio is -23.31. In terms of profitability, SUPN's ROE is -0.10%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, SUPN is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
SUPN vs AQST Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, AQST has a market cap of 480.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while AQST trades at $4.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas AQST's P/E ratio is -5.89. In terms of profitability, SUPN's ROE is -0.10%, compared to AQST's ROE of +2.44%. Regarding short-term risk, SUPN is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
SUPN vs KMDA Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, KMDA has a market cap of 439.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while KMDA trades at $7.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas KMDA's P/E ratio is 20.03. In terms of profitability, SUPN's ROE is -0.10%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, SUPN is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
SUPN vs TKNO Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TKNO has a market cap of 365.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TKNO trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TKNO's P/E ratio is -21.94. In terms of profitability, SUPN's ROE is -0.10%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, SUPN is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
SUPN vs TLRY Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TLRY has a market cap of 338.8M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TLRY trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TLRY's P/E ratio is -2.16. In terms of profitability, SUPN's ROE is -0.10%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, SUPN is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
SUPN vs EBS Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, EBS has a market cap of 325.8M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while EBS trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas EBS's P/E ratio is 4.41. In terms of profitability, SUPN's ROE is -0.10%, compared to EBS's ROE of -0.36%. Regarding short-term risk, SUPN is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
SUPN vs CGC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, CGC has a market cap of 302.8M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while CGC trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas CGC's P/E ratio is -1.60. In terms of profitability, SUPN's ROE is -0.10%, compared to CGC's ROE of -0.33%. Regarding short-term risk, SUPN is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
SUPN vs ALIM Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ALIM's P/E ratio is 5.28. In terms of profitability, SUPN's ROE is -0.10%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, SUPN is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
SUPN vs LNDC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas LNDC's P/E ratio is -4.04. In terms of profitability, SUPN's ROE is -0.10%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, SUPN is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
SUPN vs ACB Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ACB has a market cap of 251.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ACB trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ACB's P/E ratio is -2.87. In terms of profitability, SUPN's ROE is -0.10%, compared to ACB's ROE of -0.21%. Regarding short-term risk, SUPN is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
SUPN vs LFCR Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, LFCR has a market cap of 242.4M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while LFCR trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas LFCR's P/E ratio is -5.04. In terms of profitability, SUPN's ROE is -0.10%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, SUPN is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
SUPN vs TYHT Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TYHT's P/E ratio is -1.61. In terms of profitability, SUPN's ROE is -0.10%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, SUPN is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
SUPN vs SIGA Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, SIGA has a market cap of 225.6M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while SIGA trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas SIGA's P/E ratio is 11.63. In terms of profitability, SUPN's ROE is -0.10%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, SUPN is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check SIGA's competition here
Glass House Brands Inc (NYSE: GLAS)
SUPN vs GLAS Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, GLAS has a market cap of 214.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while GLAS trades at $2.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas GLAS's P/E ratio is -4.36. In terms of profitability, SUPN's ROE is -0.10%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, SUPN is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check GLAS's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
SUPN vs REPH Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas REPH's P/E ratio is -8.04. In terms of profitability, SUPN's ROE is -0.10%, compared to REPH's ROE of -0.22%. Regarding short-term risk, SUPN is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
SUPN vs THTX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas THTX's P/E ratio is -28.83. In terms of profitability, SUPN's ROE is -0.10%, compared to THTX's ROE of +0.36%. Regarding short-term risk, SUPN is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
SUPN vs ASRT Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ASRT's P/E ratio is -7.10. In terms of profitability, SUPN's ROE is -0.10%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, SUPN is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
SUPN vs DERM Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, DERM has a market cap of 146.2M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while DERM trades at $5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas DERM's P/E ratio is -23.55. In terms of profitability, SUPN's ROE is -0.10%, compared to DERM's ROE of -0.20%. Regarding short-term risk, SUPN is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check DERM's competition here
Organigram Global Inc. (NASDAQ: OGI)
SUPN vs OGI Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, OGI has a market cap of 133.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while OGI trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas OGI's P/E ratio is 2.12. In terms of profitability, SUPN's ROE is -0.10%, compared to OGI's ROE of +0.21%. Regarding short-term risk, SUPN is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check OGI's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
SUPN vs CRDL Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while CRDL trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas CRDL's P/E ratio is -4.38. In terms of profitability, SUPN's ROE is -0.10%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, SUPN is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CRDL's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
SUPN vs ORGO Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ORGO has a market cap of 131.2M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ORGO trades at $1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ORGO's P/E ratio is 34.00. In terms of profitability, SUPN's ROE is -0.10%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, SUPN is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
SUPN vs SCTL Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas SCTL's P/E ratio is -7.86. In terms of profitability, SUPN's ROE is -0.10%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, SUPN is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
SUPN vs BGM Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, BGM has a market cap of 108.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while BGM trades at $8.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas BGM's P/E ratio is -1.78. In terms of profitability, SUPN's ROE is -0.10%, compared to BGM's ROE of -0.05%. Regarding short-term risk, SUPN is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
SUPN vs PROC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas PROC's P/E ratio is 1.53. In terms of profitability, SUPN's ROE is -0.10%, compared to PROC's ROE of -2.22%. Regarding short-term risk, SUPN is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check PROC's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
SUPN vs CPIX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, CPIX has a market cap of 100.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while CPIX trades at $7.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas CPIX's P/E ratio is -16.80. In terms of profitability, SUPN's ROE is -0.10%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, SUPN is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CPIX's competition here
OptiNose, Inc. (NASDAQ: OPTN)
SUPN vs OPTN Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas OPTN's P/E ratio is -4.42. In terms of profitability, SUPN's ROE is -0.10%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, SUPN is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
SUPN vs ZOM Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ZOM's P/E ratio is -1.62. In terms of profitability, SUPN's ROE is -0.10%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, SUPN is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
SUPN vs GRVI Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas GRVI's P/E ratio is 26.05. In terms of profitability, SUPN's ROE is -0.10%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, SUPN is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
SUPN vs ZYNE Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, SUPN's ROE is -0.10%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, SUPN is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
SUPN vs ZYBT Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ZYBT has a market cap of 69.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ZYBT trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ZYBT's P/E ratio is -7.35. In terms of profitability, SUPN's ROE is -0.10%, compared to ZYBT's ROE of -0.31%. Regarding short-term risk, SUPN is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
SUPN vs SSIC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas SSIC's P/E ratio is 11.93. In terms of profitability, SUPN's ROE is -0.10%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, SUPN is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
SUPN vs VLNS Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas VLNS's P/E ratio is -1.03. In terms of profitability, SUPN's ROE is -0.10%, compared to VLNS's ROE of N/A. Regarding short-term risk, SUPN is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
SUPN vs DRRX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas DRRX's P/E ratio is -4.44. In terms of profitability, SUPN's ROE is -0.10%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, SUPN is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
SUPN vs TLPH Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TLPH trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TLPH's P/E ratio is -4.00. In terms of profitability, SUPN's ROE is -0.10%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, SUPN is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
SUPN vs INCR Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, INCR has a market cap of 52.8M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while INCR trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas INCR's P/E ratio is -4.69. In terms of profitability, SUPN's ROE is -0.10%, compared to INCR's ROE of -0.09%. Regarding short-term risk, SUPN is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
SUPN vs JUPW Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas JUPW's P/E ratio is -2.41. In terms of profitability, SUPN's ROE is -0.10%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, SUPN is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
SUPN vs QLI Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas QLI's P/E ratio is -4.92. In terms of profitability, SUPN's ROE is -0.10%, compared to QLI's ROE of -0.16%. Regarding short-term risk, SUPN is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
SUPN vs HEXO Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas HEXO's P/E ratio is -0.26. In terms of profitability, SUPN's ROE is -0.10%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, SUPN is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
SUPN vs RMTI Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, RMTI has a market cap of 30.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while RMTI trades at $7.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas RMTI's P/E ratio is -5.61. In terms of profitability, SUPN's ROE is -0.10%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, SUPN is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
SUPN vs CPHI Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, CPHI has a market cap of 29.5M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while CPHI trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas CPHI's P/E ratio is -1.59. In terms of profitability, SUPN's ROE is -0.10%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, SUPN is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CPHI's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
SUPN vs CYTH Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas CYTH's P/E ratio is -0.80. In terms of profitability, SUPN's ROE is -0.10%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, SUPN is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check CYTH's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
SUPN vs SHPH Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, SHPH has a market cap of 22.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while SHPH trades at $4.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas SHPH's P/E ratio is -0.22. In terms of profitability, SUPN's ROE is -0.10%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, SUPN is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check SHPH's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
SUPN vs TXMD Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, TXMD has a market cap of 21.5M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while TXMD trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas TXMD's P/E ratio is 94.83. In terms of profitability, SUPN's ROE is -0.10%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, SUPN is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
SUPN vs AYTU Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, AYTU has a market cap of 21.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while AYTU trades at $2.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas AYTU's P/E ratio is -1.66. In terms of profitability, SUPN's ROE is -0.10%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, SUPN is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check AYTU's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
SUPN vs EVOK Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas EVOK's P/E ratio is -7.97. In terms of profitability, SUPN's ROE is -0.10%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, SUPN is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
SUPN vs OPTH Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, OPTH has a market cap of 18.8M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while OPTH trades at $3.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas OPTH's P/E ratio is -2.10. In terms of profitability, SUPN's ROE is -0.10%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, SUPN is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
SUPN vs ACRX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ACRX's P/E ratio is -0.31. In terms of profitability, SUPN's ROE is -0.10%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, SUPN is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
SUPN vs CABR Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, CABR has a market cap of 10.9M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while CABR trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas CABR's P/E ratio is -1.54. In terms of profitability, SUPN's ROE is -0.10%, compared to CABR's ROE of -3.86%. Regarding short-term risk, SUPN is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
SUPN vs AGRX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas AGRX's P/E ratio is -0.89. In terms of profitability, SUPN's ROE is -0.10%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, SUPN is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
SUPN vs NLTX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas NLTX's P/E ratio is -0.28. In terms of profitability, SUPN's ROE is -0.10%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, SUPN is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check NLTX's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
SUPN vs INM Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, INM has a market cap of 7.6M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while INM trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas INM's P/E ratio is -0.45. In terms of profitability, SUPN's ROE is -0.10%, compared to INM's ROE of -1.35%. Regarding short-term risk, SUPN is more volatile compared to INM. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check INM's competition here
Lannett Company, Inc. (NYSE: LCI)
SUPN vs LCI Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas LCI's P/E ratio is -0.04. In terms of profitability, SUPN's ROE is -0.10%, compared to LCI's ROE of +1.66%. Regarding short-term risk, SUPN is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
SUPN vs ADMP Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ADMP's P/E ratio is -0.08. In terms of profitability, SUPN's ROE is -0.10%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, SUPN is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check ADMP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
SUPN vs SNOA Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, SNOA has a market cap of 5.4M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while SNOA trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas SNOA's P/E ratio is -1.01. In terms of profitability, SUPN's ROE is -0.10%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, SUPN is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
SUPN vs MNK Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas MNK's P/E ratio is -0.44. In terms of profitability, SUPN's ROE is -0.10%, compared to MNK's ROE of -0.36%. Regarding short-term risk, SUPN is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
SUPN vs FLGC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas FLGC's P/E ratio is -0.19. In terms of profitability, SUPN's ROE is -0.10%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, SUPN is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check FLGC's competition here
cbdMD, Inc. (AMEX: YCBD)
SUPN vs YCBD Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, YCBD has a market cap of 4M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while YCBD trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas YCBD's P/E ratio is -0.87. In terms of profitability, SUPN's ROE is -0.10%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, SUPN is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
SUPN vs GELS Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, GELS has a market cap of 3.9M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while GELS trades at $0.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas GELS's P/E ratio is -0.98. In terms of profitability, SUPN's ROE is -0.10%, compared to GELS's ROE of -0.36%. Regarding short-term risk, SUPN is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check GELS's competition here
Akanda Corp. (NASDAQ: AKAN)
SUPN vs AKAN Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, AKAN has a market cap of 2.7M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while AKAN trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas AKAN's P/E ratio is -0.02. In terms of profitability, SUPN's ROE is -0.10%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, SUPN is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
SUPN vs PLXP Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas PLXP's P/E ratio is -0.22. In terms of profitability, SUPN's ROE is -0.10%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, SUPN is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for SUPN.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
SUPN vs UPC Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while UPC trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas UPC's P/E ratio is -0.48. In terms of profitability, SUPN's ROE is -0.10%, compared to UPC's ROE of -0.03%. Regarding short-term risk, SUPN is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
SUPN vs ATNX Comparison October 2026
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SUPN stands at 2.3B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, SUPN is priced at $41.59 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SUPN currently has a P/E ratio of 13.02, whereas ATNX's P/E ratio is -0.02. In terms of profitability, SUPN's ROE is -0.10%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, SUPN is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for SUPN.Check ATNX's competition here